A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : ADA / adalimumab

[Related PubMed/MEDLINE]
Total Number of Papers: 417
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   ADA  (>> Co-occurring Abbreviation)
Long Form:   adalimumab
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study. DAS, ESR, HAQ-DI, mTSS, RA
2020 A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. csDMARDs, IXE, PsA
2020 Clinical utility of serum concentrations of adalimumab as predictor of treatment adherence. IA, IBD, MGT, MPR, SC
2020 Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis. DAS28, RA, TCZ
2020 Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naive Korean Patients with Ulcerative Colitis: A Population-Based Study. aHR, CI, ER, IFX, UC
2020 Efficacy of ustekinumab versus advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. GOL, IFX, NMA, TOF, UST, VDZ
2020 Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe. IFX, IM, UC, US
2020 Whole-body Magnetic Resonance Imaging Inflammation in Peripheral Joints and Entheses in Axial Spondyloarthritis: Distribution and Changes during Adalimumab Treatment. axSpA, WB-MRI
2019 A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-alpha Inhibitor-naive and Non-naive Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease. CD, IFX, OR
10  2019 Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study. BCVA, DMARD
11  2019 Adalimumab drug and antidrug antibody levels do not predict flare risk after stopping adalimumab in RA patients with low disease activity. ---
12  2019 Adalimumab for nail psoriasis: efficacy and safety over 52weeks from a phase-3, randomized, placebo-controlled trial. OLE
13  2019 Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry. ACR, AEs, JIA, MTX, SAEs
14  2019 Administration Timing Is the Best Clinical Outcome Predictor for Adalimumab Administration in Crohn's Disease. CDs
15  2019 An Analysis of the Biological Disease-modifying Antirheumatic Drug-free Condition of Adalimumab-treated Rheumatoid Arthritis Patients. bDMARD, csDMARDs, DAS28-CRP, mHAQs, MTX, RA
16  2019 An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: modeling the cost of treatment strategies in the United States. GOL, IFX, PMPM, TNFis, TOFA, UC, VEDO
17  2019 Anti-adalimumab antibodies kinetics: an early guide for juvenile idiopathic arthritis (JIA) switching. AAA, BL, JIA
18  2019 Anti-tumor necrosis factor agents in sarcoidosis: A systematic review of efficacy and safety. anti-TNFs, IFX, RCTs
19  2019 Association of anti-cyclic citrullinated peptide antibody with clinical features in patients with psoriatic arthritis. CASPAR, DMARDs, ETN, IFX, PsA, RF, TNF
20  2019 Association of Pharmacological Biomarkers with Treatment Response and Longterm Disability in Patients with Psoriatic Arthritis: Results from OUTPASS. ADAb, HAQ, PsA, TNFi
21  2019 Chlamydia-induced reactive arthritis diagnosed during gout flares: A case report and cumulative effect of inflammatory cytokines on chronic arthritis. CRP, HLA, MSU, MTP, ReA
22  2019 Comparative Effectiveness of Ustekinumab Versus Adalimumab in Induction of Clinical Response and Remission in Crohn's Disease: Experience of a Real-World Cohort at a Tertiary Care Inflammatory Bowel Disease Referral Center. CD, CI, OR, TNF, UST
23  2019 Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. IFX, UME
24  2019 Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab. IFX, UC, VDZ
25  2019 Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behcet's Disease: National Multicenter Study of 177 Cases. BD, IFX
26  2019 Comparison of a new rapid method for the determination of adalimumab serum levels with two established ELISA kits. ELISA, IBDs, LT, PM, QB, TDM
27  2019 Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab. ICER, IPTW, IXE, PMPM, PsO, SEC
28  2019 Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis. DAS28-ESR, IL-6, MCH, MTX, RA, TOC
29  2019 Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis. DLQI, FAE, INF, IXE, MID, MTX, PASI, SEC
30  2019 Demographics and clinical characteristics associated with sustained remission and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab. RA
31  2019 Distinct Association of Serum Vitamin D Concentration with Disease Activity and Trough Levels of Infliximab and Adalimumab during Inflammatory Bowel Disease Treatment. anti-TNFalpha, CRP, IBD, IFX, TC, VitD
32  2019 Do Anti-TNF Agents Increase the Risk of Inflammatory Bowel Disease Evolution in Patients with Ankylosing Spondylitis? Real Life Data. AS, ETN, GO, IBD, INF, TNF
33  2019 Drug Levels and Antibodies Against TNF-blockers in Spondyloarthritis and Rheumatoid Arthritis are Associated with the Activity but they do Not Predict it. ADAs, CDAI, ETN, IFX, RA, SDAI, SpA
34  2019 Drug Retention Rate and Causes of Discontinuation of Adalimumab in Uveitis: Real-World Data from the Biotherapies in Uveitis (BioUvea) Study Group. BioUvea, DRR, DRT, IMT, NIU, PHM
35  2019 Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study. ABT, bDMARDs, CZP, ETN, GLM, IFX, MTX, PSL, RA, TCZ
36  2019 Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study. ABT, bDMARDs, CZP, ETN, GLM, IFX, RA, TCZ
37  2019 Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale. LSM, MCID, PASS, RA, RAID
38  2019 Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up. TB, TMS
39  2019 Efficacy and survival of biologic agents in psoriasis: a practical real-life 12-year experience in a French dermatology department. ETA, UST
40  2019 Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn's disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience. CD, CR, PCDAI
41  2019 Genetic markers associated with clinical and radiographic response in adalimumab plus methotrexate- or methotrexate-treated rheumatoid arthritis patients in OPTIMA. FcgRIIb, IL-4R, MTX, OPTIMA, RA, SE, SNP
42  2019 Impact of Online Prescription Management Systems on Biologic Treatment Initiation. HCPro
43  2019 Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity. DAPSA, MDA, PASDAS, PBO, TA
44  2019 Live Zoster Vaccine in Patients with Rheumatoid Arthritis Treated with Tofacitinib with or without Methotrexate, or Adalimumab with Methotrexate. HZ, IR, LZV, MTX, RA
45  2019 Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. DLQI, HiSCR, HS, OLE, PRRs
46  2019 Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics. CD, IFX, LOR
47  2019 Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis. IFX
48  2019 Longterm Drug Survival of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis. CZP, ETN, GOL, IFX, RA
49  2019 New adalimumab formulation associated with less injection site pain and improved motivation for treatment. ---
50  2019 Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study. GOL, IFX, LOR, s.c, UC
51  2019 Participation in an innovative patient support program reduces prescription abandonment for adalimumab-treated patients in a commercial population. CI, OR, PSP
52  2019 Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending. PSP
53  2019 Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial. MTX, PROs, PtGA, RA
54  2019 Persistence to subcutaneous biological agents in Hungarian patients treated for inflammatory arthritis. CZP, GLM
55  2019 Polarization of Rheumatoid Macrophages by TNF Targeting Through an IL-10/STAT3 Mechanism. bDMARDs, ETA, RA, RTX, TCZ
56  2019 Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. AZA, CD, EQ-5D, HRQoL
57  2019 Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab. CRP, csDMARD, mTSS, PsA
58  2019 Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA. AS, CI, ETN, GISEA, HR, INF, IQR, PsA, SIs, SpA, TNF
59  2019 Real-world comparative effectiveness of adalimumab, etanercept and methotrexate: a Swedish register analysis. DLQI, ETN, HR, MTX, PASI
60  2019 Regression of Optic Disc Neovascularization (NVD) in a Patient with Behcet's Disease Treated with Oral Corticosteroids and Adalimumab (ADA). ---
61  2019 Relationship between Serum Adalimumab Levels and Clinical Outcome in the Treatment of Inflammatory Bowel Disease. ---
62  2019 Results of a retrospective study on the efficacy and safety of adalimumab 80mg administrated every other week in patients with psoriasis at a single Japanese institution. TNF
63  2019 Retrospective Analysis of the Impact of Adalimumab Initiation on Corticosteroid Utilization and Medical Costs Among Biologic-Naive Patients with Rheumatoid Arthritis. CI, OR, RA
64  2019 Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry 7-Year Interim Results. ADAMTX, AEs, MTX, pcJIA, PY
65  2019 Sex Differences in Response to TNF-Inhibiting Drugs in Patients With Spondyloarthropathies or Inflammatory Bowel Diseases. IBD, IFX, SpA, TNFi
66  2019 Statement of the expert group on the current practice and prospects for the treatment of complex perirectal fistulas in the course of Crohn's disease. CD, CER, IFX
67  2019 Successful closure of ileostomy in a patient with intestinal Behcet's disease after therapy with adalimumab: A case report. BD
68  2019 Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study. IT, LTE, MTX
69  2019 Tocilizumab and the risk of respiratory adverse events in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomised controlled trials. AEs, PBO, RCT, RR, SAEs
70  2019 Validation of a population pharmacokinetic model of adalimumab in a cohort of patients with inflammatory bowel disease. ATL, IBD, IPRED, PK, PRED
71  2019 Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2). CFCR, Con, Dis, ER
72  2019 [A case of refractory pouchitis following surgery for ulcerative colitis successfully treated with adalimumab]. IPAA, TNF-alpha, UC
73  2018 Adalimumab persistence for inflammatory bowel disease in veteran and insured cohorts. IBD, OR, VHA
74  2018 Adalimumab therapy in hepatitis B virus-negative polyarteritis nodosa: A case report. PAN
75  2018 Adalimumab-Based Treatment Versus Disease-Modifying Antirheumatic Drugs for Venous Thrombosis in Behcet's Syndrome: A Retrospective Study of Seventy Patients With Vascular Involvement. BS, DMARD
76  2018 Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis aHR, AMCs, ETN, IFX, UST
77  2018 An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective. ACR, ETN, MTX, PMPM, RA, TNFi
78  2018 Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter a panel of B-cell and T-cell subsets in 1-year-old infants. anti-TNF, CZP, IFN-gamma, IFX
79  2018 Anti-TNF Levels in Cord Blood at Birth are Associated with Anti-TNF Type. IBD, IFX
80  2018 Clinical Responses and Synovial Vascularity in Obese Rheumatoid Arthritis Patients Treated with Adalimumab and Methotrexate. ACR, LDA, MTX, RA
81  2018 Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naive Crohn's Disease. CD, IFX
82  2018 Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases. ADAs, AS, CERT, ETA, GOL, HLA, IFX, PsA, RA
83  2018 Cumulative retention rate of adalimumab in patients with Behcet's disease-related uveitis: a four-year follow-up study. BD, DMARDs
84  2018 Defining an Optimal Adherence Threshold for Patients Taking Subcutaneous Anti-TNFs for Inflammatory Bowel Diseases. IBD, MPR
85  2018 Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate. MTX, TCZ, TOF
86  2018 Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study. ABT, bDMARDs, CZP, DAS28-ESR, ETN, GLM, IFX, RA, TCZ
87  2018 Economic impact of adalimumab treatment in Japanese patients with rheumatoid arthritis from the adalimumab non-interventional trial for up-verified effects and utility (ANOUVEAU) study. AI, ANOUVEAU, HM, OWI, PTW, PW, RA, WPAI/RA
88  2018 Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: A real-life multicenter, observational study in primary inflammatory bowel disease centers. CI, IBD, UC
89  2018 Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial. HA, PGA, PhGA, VAS, WOMAC
90  2018 Efficacy and Safety of Adalimumab in Pediatric Ulcerative Colitis: A Real-life Experience from the SIGENP-IBD Registry. IFX, UC
91  2018 Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review. AEs, RCTs, VA
92  2018 Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1). ACR, EPP, IXE, PBO, PsA
93  2018 Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease. CD, ED, IFX, TNF-alpha
94  2018 Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies. BCVA, cDMARDs, IFX, RV, TNF
95  2018 High rate of improvement in serum matrix metalloproteinase-3 levels at 4 weeks predicts remission at 52 weeks in RA patients treated with adalimumab. AUC, CI, MMP-3, OR, RA
96  2018 Impact of the Adalimumab Patient Support Program on Clinical Outcomes in Ankylosing Spondylitis: Results from the COMPANION Study. AC-PSP, AS, BASDAI, CCCs, RR, TNF
97  2018 Impact of the Adalimumab Patient Support Program's Care Coach Calls on Persistence and Adherence in Canada: An Observational Retrospective Cohort Study. CCCs, PSP
98  2018 Is Patient Support Program Participation Associated with Longer Persistence and Improved Adherence Among New Users of Adalimumab? A Retrospective Cohort Study. CHS, MPR, PSP
99  2018 Long-term safety and effectiveness of adalimumab for the treatment of Japanese patients with rheumatoid arthritis: 3-year results from a postmarketing surveillance of 552 patients. ADRs, PYs, RA, SADRs
100  2018 Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis. AE, IFX, JIA